Sanofi and Regeneron Pharmaceuticals are set to continue the Phase II/III clinical trial of Kevzara (sarilumab) in hospitalised patients having critical respiratory illness caused by Covid-19.

The move is based on a recommendation by the Independent Data Monitoring Committee (IDMC), which reviewed available Phase II and Phase III findings.

Sanofi and Regeneron will immediately amend the trial protocol to enrol only critical patients in 400mg Kevzara or placebo arms, and a 200mg dose of the drug will be discontinued.

Read the full article here